National Stock Exchange

Only 18% of approved pharmaceutical units have received incentives under the government’s technology-upgradation scheme due to delays in meeting manufacturing norms. Compliance remains low despite the scheme’s goal of aiding MSME units. The government has extended the deadline to December 2025 and is addressing operational difficulties for smaller companies, as urged by a parliamentary panel.